MOLN.SW Molecular Partners AG (SIX) CHF 3.75 pre-earnings 11 Mar 2026: key metrics

MOLN.SW stock is trading at CHF 3.75 intraday on SIX on 11 Mar 2026 as investors position ahead of Molecular Partners AG’s earnings report due 12 Mar 2026. Volume sits at 15,019.00 shares versus a 50-day average of 22,236.00, and the stock is up 2.60% today. Key numbers to watch are EPS -1.62 and a negative PE of -2.31, which underline the clinical-stage firm’s loss-making profile as clinical readouts and partner updates will drive the print. We use Meyka AI-powered market analysis to map scenarios and price targets.

MOLN.SW stock: Earnings schedule, what to expect

Molecular Partners AG reports after European markets on 12 Mar 2026, which makes today’s intraday price action critical for short-term traders. The company is clinical-stage and earnings will focus on cash guidance, R&D milestones, and updates on Phase III and Phase I programs. One clear market driver is any commentary on partner programs with Novartis, Amgen or AbbVie that could affect near-term funding or milestones.

Financials and valuation: loss-making biotech metrics

Molecular Partners shows EPS -1.62 and a trailing PE of -2.31, reflecting consistent R&D spending and no revenue per share. The balance sheet reads with cash per share 2.79 and book value per share 2.55, while market cap is CHF 140,246,820.00 on 37,399,152.00 shares outstanding. Current ratio is strong at 9.28, signalling liquidity, but free cash flow per share is negative -1.44 which highlights ongoing funding needs.

Catalysts ahead of earnings and near-term drivers

Investors will watch updates on Abicipar and the MP03xx oncology programs and any regulatory timing for Phase III assets. Clinical readouts, partnership milestone payments, or changes to R&D spend will move the stock. Given the collaboration history with Novartis and others, pipeline-related news can translate to sharp intraday moves on SIX.

Technical and trading flow for MOLN.SW stock

Intraday range is CHF 3.69 to CHF 3.77, with the 50-day average at CHF 3.49 and 200-day average at CHF 3.16. RSI sits at 52.23 and ADX at 27.08, suggesting a neutral to mildly trending market. Average volume is 22,236.00; today’s volume at 15,019.00 is below average but relative volume is 1.26. Traders should watch Bollinger middle band CHF 3.75 and the ATR 0.19 for expected intraday volatility.

Meyka AI rates MOLN.SW with a score out of 100 and forecast

Meyka AI rates MOLN.SW with a score out of 100: 65.11 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF 2.97, quarterly CHF 2.64, and yearly CHF 2.35. Versus the current price CHF 3.75, the yearly projection implies -37.33% downside. Forecasts are model-based projections and not guarantees.

Risks and opportunities for investors

Key risks include continuing negative earnings, potential trial delays, and the need for further financing, all common to clinical-stage biotechs. Opportunities include positive clinical readouts, milestone payments from collaborators, or favourable regulatory news that could push the price above the recent high CHF 4.14. Sector context matters: Healthcare peers trade at an average PE 30.19, underscoring valuation dispersion for small biotech names.

Final Thoughts

MOLN.SW stock trades at CHF 3.75 on SIX on 11 Mar 2026 with earnings due 12 Mar 2026. The company is loss-making with EPS -1.62 and clear pipeline-driven sensitivities. Meyka AI’s forecast model projects a yearly target of CHF 2.35, implying -37.33% versus today’s price, while a constructive scenario price target of CHF 4.50 implies +20.00% upside. Our proprietary grade (B, HOLD) reflects mixed fundamentals, solid liquidity and pipeline risk. Traders should focus on guidance, milestone disclosures and partner updates in the earnings release. All forecasts are model-based projections and not guarantees. For live quotes see Molecular Partners and our platform MOLN.SW on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.